Pure Global
NCT06155396

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

A Single-Arm, Open- Label, Multicenter Phase II Study of RC48-ADC Vedicilumab for Injection in Combination With Zimberelimab Injection for the Treatment ,at Least First-line Platinum-containing Standard Therapy Failed in HER2-expressing Subject With Recurrent or Metastatic Cervical Cancer
RemeGen Co., Ltd.·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cervical Cancer
Drug/Device/Intervention
Disitamab Vedotin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
RemeGen Co., Ltd.
Location
Bengbu,Beijing,Chongqing,Nanning,Changsha,Nanchang,Shenyang,Jinan,Shanghai,Tianjin,Kunming,Hangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Dec 08, 2023
End date
Dec 31, 2027
Enrollment
116 participants
Primary outcome

Safety run-in ：Safety(adverse event),Dose extension period ：Objective Response Rate (ORR)

Summary

This study will evaluate the efficacy,safety of RC48-ADC in Combination with Zimberelimab
 Injection for the Treatment ,at least first-line platinum-containing standard therapy failed
 in HER2-expressing subject with Recurrent or Metastatic Cervical Cancer

ICD-10 classifications
Severe cervical dysplasia, not elsewhere classifiedMild cervical dysplasiaModerate cervical dysplasiaCarcinoma in situ: Cervix, unspecifiedCervical root disorders, not elsewhere classified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155396
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06155396 through Pure Global AI's free database. This Phase 2 trial is sponsored by RemeGen Co., Ltd. and is currently Not yet recruiting. The study focuses on Cervical Cancer. Target enrollment is 116 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.